Supplementary Table 1. Classes of ADM used at baseline and follow-ups.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Baseline | | 6 Months  (*n* = 32) | 12 Months  (*n* = 30) |
| Admission  (*n* = 40) | Discharge  (*n* = 71) |
| SSRI | 24 (60.0 %) | 40 (56.3 %) | 25 (78.1 %) | 25 (83.3 %) |
| SSNRI | 11 (27.5 %) | 14 (19.7 %) | 4 (12.5 %) | 3 (10.0 %) |
| NASSA | 7 (17,5 %) | 21 (29.5 %) | 1 (3.1 %) | 4 (13.3 %) |
| TTA | 4 (10,0 %) | 6 (8.4 %) | 3 (9.4 %) | 0 |
| MAO inhibitor | 0 | 0 | 1 (3.1 %) | 1 (3.3 %) |

ADM = Antidepressant medication, MAO = Monoamine oxidase, NASSA = noradrenergic and specific serotonergic antidepressant, SSNRI = Selective serotonin and norepinephrine reuptake inhibitor, SSRI = Selective serotonin reuptake inhibitor, Tri-/Tetracyclic antidepressant.

**Concordance:** Admission: 3 used SSRI + NASSA, 2 used SSNRI + NASSA, 1 used Tri-/Tetracyclic antidepressant + NASSA. Discharge: 7 used SSRI + NASSA, 3 used SSNRI + NASSA. 6-Months: 1 used SSRI + NASSA. 12-months: 2 used SSRI + NASSA, 1 used SSNRI + NASSA.